¼¼°èÀÇ Æú¸®´ºÅ¬·¹¿ÀƼµå ÁÖ»çÁ¦ ½ÃÀå
Polynucleotides Injectables
»óǰÄÚµå : 1784025
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 286 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,150,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,452,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Æú¸®´ºÅ¬·¹¿ÀƼµå ÁÖ»çÁ¦ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 2¾ï 6,470¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 1¾ï 2,380¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â Æú¸®´ºÅ¬·¹¿ÀƼµå ÁÖ»çÁ¦ ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 13.5%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 2¾ï 6,470¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®µÇ°í ÀÖ´Â ºÎ¹® Áß ÇϳªÀÎ ´«Àº CAGR 12.4%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 1¾ï 1,830¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÔ¼ú ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 14.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 3,370¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 17.9%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Æú¸®´ºÅ¬·¹¿ÀƼµå ÁÖ»çÁ¦ ½ÃÀåÀº 2024³â¿¡´Â 3,370¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 5,570¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 17.9%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 10.0%¿Í 12.0%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 10.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Æú¸®´ºÅ¬·¹¿ÀƼµå ÁÖ»çÁ¦ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Æú¸®´ºÅ¬·¹¿ÀƼµå ÁÖ»çÁ¦¶õ ¹«¾ùÀ̸ç, ¿Ö ¹Ì¿ëÀÇ·á¿Í Àç»ýÀÇ·á¿¡ º¯È­¸¦ °¡Á®¿À´Â°¡?

Æú¸®´ºÅ¬·¹¿ÀƼµå ÁÖ»çÁ¦´Â ÇǺÎÀÇ Áú, º¸½À, Á¶Á÷ ȸº¹À» °³¼±Çϱâ À§ÇØ ¹Ì¿ë ÀÇ·á ¹× Àç»ý Ä¡·á¿¡ »ç¿ëµÇ´Â »õ·Î¿î Á¾·ùÀÇ »ýü ÀÚ±Ø ÁÖ»çÁ¦ÀÔ´Ï´Ù. Æú¸®´ºÅ¬·¹¿ÀƼµå(PN)´Â õ¿¬ DNA³ª RNA¿¡¼­ ÃßÃâÇÑ Àå¼âÀÇ ´ºÅ¬·¹¿ÀƼµå¸¦ ¸»Çϸç, ÀϹÝÀûÀ¸·Î ¿¬¾î³ª ¼Û¾îÀÇ DNA¿¡¼­ ÃßÃâµË´Ï´Ù. ÁÖ·Î º¼·ýÀ» ÁÖ´Â ±âÁ¸ÀÇ ÇǺΠÇÊ·¯¿Í ´Þ¸®, Æú¸®´ºÅ¬·¹¿ÀƼµå ÁÖ»çÁ¦´Â ¼¶À¯¾Æ¼¼Æ÷ÀÇ È°¼ºÀ» ÀÚ±ØÇϰí, ¼öºÐ °ø±ÞÀ» Áõ°¡½Ã۰í, ÇǺÎÀÇ Åº·ÂÀ» Áõ°¡½ÃÄÑ Àå±âÀûÀÎ ÇǺΠȸÃáÀ¸·Î À̾îÁý´Ï´Ù.

PN ÁÖ»çÁ¦´Â ÀÚ¿¬½º·´°í Àç»ýÀûÀÎ ¹Ì¿ë Á¢±Ù¹ýÀ¸·Î Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. ¾ó±¼ÀÇ ±¸Á¶¸¦ ¹Ù²ÙÁö ¾Ê°í ¼Õ»óµÈ ÇǺθ¦ º¹±¸Çϰí, ÀÜÁÖ¸§À» ÁÙÀ̰í, ÇǺΠ°áÀ» °³¼±Çϰí, ź·ÂÀ» Çâ»ó½Ãŵ´Ï´Ù. µû¶ó¼­ º¼·ý¾÷ È¿°úº¸´Ù´Â ¼¶¼¼Çϰí ÀÚ¿¬½º·¯¿î ¿Ü¸ð °³¼±À» ¿øÇϴ ȯÀÚ¿¡°Ô ÀÌ»óÀûÀÔ´Ï´Ù. ¶ÇÇÑ Ç׿°Áõ ÀÛ¿ë°ú Ç×»êÈ­ ÀÛ¿ëÀÌ ÀÖ¾î ±â¹Ì, ¿©µå¸§ ÈäÅÍ, ·¹ÀÌÀú Á¶»ç ÈÄ ÇǺΠȸº¹¿¡µµ È¿°úÀûÀ̾ ÇǺΰú¿¡¼­ ±× ¾²ÀÓ»õ°¡ ´õ¿í ³Ð¾îÁö°í ÀÖ½À´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀº ¾î¶»°Ô Æú¸®´ºÅ¬·¹¿ÀƼµå ÁÖ»çÁ¦¸¦ °­È­Çϴ°¡?

»ý¸í°øÇÐ ¹× »ý¹°°øÇÐÀÇ Çõ½ÅÀº Æú¸®´ºÅ¬·¹¿ÀƼµå ÁÖ»çÁ¦ÀÇ Á¦ÇüÀ» ¹ßÀü½ÃÄÑ ´õ È¿°úÀûÀ̰í, ´õ ¿À·¡ Áö¼ÓµÇ¸ç, ´õ ¾ÈÀüÇÑ ÀÓ»óÀû »ç¿ëÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä ¹ßÀü Áß Çϳª´Â »ýüÀûÇÕ¼ºÀ» ³ôÀÌ°í ¸é¿ª¿ø¼ºÀ» ³·Ãá °íµµ·Î Á¤Á¦µÇ°í ¾ÈÁ¤È­µÈ Æú¸®´ºÅ¬·¹¿ÀƼµå »ç½½ÀÇ °³¹ßÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Ã·´Ü Á¦Çü ´öºÐ¿¡ PN ÁÖ»çÁ¦´Â ÇǺο¡ Àß ½º¸çµé¾î ºÎÀÛ¿ë°ú ¿°ÁõÀÇ À§ÇèÀ» ÃÖ¼ÒÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¶Ç ´Ù¸¥ Áß¿äÇÑ Çõ½ÅÀº ÇǺο¡¼­ »ý¹°ÇÐÀû Ȱ¼ºÀ» ¿¬ÀåÇÏ´Â °¡±³ Æú¸®´ºÅ¬·¹¿ÀƼµåÀÇ ÅëÇÕÀÔ´Ï´Ù. ºü¸£°Ô ºÐÇØµÇ´Â ºñÁ¤Á¦ PN°ú ´Þ¸®, ÀÌ »õ·Î¿î Á¦ÇüÀº Àå±â°£¿¡ °ÉÃÄ Áö¼ÓÀûÀÎ ÇǺΠȸÃá°ú º¸½ÀÀ» °¡´ÉÇÏ°Ô ÇÏ¿© ÀæÀº Ä¡·áÀÇ Çʿ伺À» ÁÙ¿©ÁÝ´Ï´Ù. ÃÖ±Ù¿¡´Â Æú¸®´ºÅ¬·¹¿ÀƼµå¸¦ È÷¾Ë·ç·Ð»ê, ÆéŸÀ̵å, Ç×»êÈ­Á¦¿Í °áÇÕÇÏ¿© º¸½ÀÀ» °­È­Çϰí, Äݶó°Õ ÇÕ¼ºÀ» ÃËÁøÇϰí, ´ÙÃþÀûÀÎ ÇǺΠº¹±¸¸¦ ÇÏ´Â ÁÖ»çÁ¦ ºê·£µåµµ ÀÖ½À´Ï´Ù.

¶ÇÇÑ, PN ±â¹Ý ¸ÞÁ¶Å×¶óÇÇ ±â¼úÀÇ ÃâÇöÀº ÇǺΠȸÃá Ä¡·á ¹æ¹ý¿¡ Çõ¸íÀ» ºÒ·¯ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ÁøÇÇ Ç¥Ãþ¿¡ Æú¸®´ºÅ¬·¹¿ÀƼµå¸¦ ¹Ì¼¼ ÁÖÀÔÇϸé Á¦¾îµÈ ¹Ì¼¼ ¿Ü»óÀ» ÀÏÀ¸ÄÑ ÀÚ¿¬Àû Á¶Á÷ Àç»ýÀ» À¯µµÇÕ´Ï´Ù. ¸¶ÀÌÅ©·Î ´Ïµé ¹× ·¹ÀÌÀú Ä¡·á¿Í ÇÔ²² PN ÁÖ»çÁ¦´Â ÇǺΠȸº¹À» °¡¼ÓÈ­Çϰí Ä¡·á È¿°ú¸¦ ³ôÀ̱â À§ÇØ ÀüüÀûÀÎ ÇǺΠȸÃá ÇÁ·ÎÅäÄÝ¿¡ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÛ¿ëÇÕ´Ï´Ù.

¶ÇÇÑ, AI¸¦ Ȱ¿ëÇÑ ÇǺΠºÐ¼®°ú ¸ÂÃãÇü ÀÇ·á´Â ½Ã¼úÀÚ°¡ °³°³ÀÎÀÇ ÇǺΠ»óÅ¿¡ µû¶ó Æú¸®´ºÅ¬·¹¿ÀƼµå Ä¡·á¸¦ Á¶Á¤ÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. 3D ¿µ»ó°ú AI¸¦ Ȱ¿ëÇÑ Áø´Ü µµ±¸ÀÇ µµ¿òÀ¸·Î ÀÇ»ç´Â ȯÀÚº°·Î ÃÖÀûÀÇ PN Á¦Á¦¿Í ÁÖÀÔ ÇÁ·ÎÅäÄÝÀ» Á¤È®ÇÏ°Ô °áÁ¤ÇÏ¿© È¿°ú¿Í ȯÀÚ ¸¸Á·µµ¸¦ ±Ø´ëÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Æú¸®´ºÅ¬·¹¿ÀƼµå ÁÖ»çÁ¦ ¼ö¿ä¸¦ ÁÖµµÇÏ´Â ÁÖ¿ä ½ÃÀå µ¿ÇâÀº?

Æú¸®´ºÅ¬·¹¿ÀƼµå ÁÖ»çÁ¦¿¡ ´ëÇÑ ¼¼°è ¼ö¿ä´Â Àç»ý ¹Ì¿ë, ÇǺΠ°Ç°­ ÃÖÀûÈ­, ÃÖ¼Òħ½À Ä¡·á·ÎÀÇ ÀüȯÀ» ¹Ý¿µÇÏ´Â ¸î °¡Áö ÁÖ¿ä Æ®·»µå¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù.

ȯÀÚ¿Í ½Ã¼úÀÚµéÀº ÀÎÀ§ÀûÀ¸·Î º¼·ýÀ» ´Ã¸®´Â °ÍÀÌ ¾Æ´Ï¶ó ½ÅüÀÇ ÀÚ¿¬Àû °úÁ¤¿¡ ÀÛ¿ëÇÏ´Â »ýü ÀÚ±Ø Ä¡·á¸¦ Á¡Á¡ ´õ ¼±È£Çϰí ÀÖ½À´Ï´Ù. Æú¸®´ºÅ¬·¹¿ÀƼµå ÁÖ»çÁ¦´Â Äݶó°Õ ¸®¸ðµ¨¸µ°ú ¼¼Æ÷ Àç»ýÀ» ÃËÁøÇÏ¿© ±âÁ¸ ÇÊ·¯Ã³·³ Áï°¢ÀûÀ̰í ÀϽÃÀûÀÎ È¿°ú°¡ ¾Æ´Ñ ÀÚ¿¬½º·´°í Àå±âÀûÀÎ °á°ú¸¦ Á¦°øÇÔÀ¸·Î½á ÀÌ·¯ÇÑ Ãß¼¼¿¡ ºÎÇÕÇÕ´Ï´Ù.

ÀþÀº ȯÀÚµéÀº ´«¿¡ º¸ÀÌ´Â ³ëÈ­ ¡Èİ¡ ³ªÅ¸³¯ ¶§±îÁö ±â´Ù¸®Áö ¾Ê°í, ÇǺΠ°Ç°­°ú Àå¼ö¸¦ Áö¿øÇÏ´Â ¿¹¹æÀû ½ºÅ²Äɾî Ä¡·á¸¦ ¿øÇϰí ÀÖ½À´Ï´Ù. PN ÁÖ»çÁ¦´Â ÇöÀç 'ÇǺΠÀå¼ö' Àü·«ÀÇ ÀÏȯÀ¸·Î ÆÇ¸ÅµÇ°í ÀÖÀ¸¸ç, ÁÖ¸§ÀÌ ´«¿¡ ¶ç°Ô ³ªÅ¸³ª±â Àü Ãʱâ Äݶó°Õ °¨¼Ò, Å»¼ö, »êÈ­ ½ºÆ®·¹½º¸¦ Ç¥ÀûÀ¸·Î »ï°í ÀÖ½À´Ï´Ù.

óÀ½¿¡´Â Æú¸®´ºÅ¬·¹¿ÀƼµå ÁÖ»çÁ¦°¡ ¾ó±¼ ȸÃá¿¡ ³Î¸® »ç¿ëµÇ¾úÁö¸¸, ÇöÀç´Â ¸ñÀÇ Åº·Â, µ¥ÄÝÅ×ÀÇ È¸Ãá, ¼ÕÀÇ È°·Â, ¸ð¹ß ȸº¹À» À§ÇÑ µÎÇÇ Ä¡·á¿¡µµ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ±× Àç»ý Ư¼ºÀ¸·Î ÀÎÇØ ÈäÅÍ ±³Á¤, ư»ì Ä¡·á, ¼ö¼ú ÈÄ Ä¡À¯¿¡µµ Ȱ¿ëµÇ°í ÀÖ¾î ½ÃÀåÀÇ °¡´É¼ºÀº ´õ¿í ³Ð¾îÁö°í ÀÖ½À´Ï´Ù.

PN ÁÖ»çÁ¦´Â °íÁÖÆÄ(RF), ·¹ÀÌÀú Ä¡·á, ¸¶ÀÌÅ©·Î´Ïµé, Ç÷¼ÒÆÇdzºÎÇ÷Àå(PRP), ÇǺΠÇÊ·¯ µî°úÀÇ º´¿ëÄ¡·á¿¡ Æ÷ÇԵǴ °æ¿ì°¡ ¸¹½À´Ï´Ù. ÀÌ·¯ÇÑ ¸ÖƼ¸ð´Þ Á¢±Ù¹ýÀº ÇǺΠÀç»ýÀ» ÁõÆø½Ã۰í, Ä¡·á È¿°ú¸¦ ³ôÀ̰í, Ä¡·á ±â°£À» ¿¬Àå½Ãŵ´Ï´Ù. Ŭ¸®´ÐÀº PN ÁÖ»çÁ¦¿Í ´Ù¸¥ »ýüÀÚ±Ø Ä¡·á¸¦ °áÇÕÇÑ ÇÁ·ÎÅäÄÝÀ» äÅÃÇÏ¿©, ´Üµ¶ ½Ã¼úÀÌ ¾Æ´Ñ ÀüüÀûÀÎ ÇǺΠȸº¹À» ¿øÇϴ ȯÀڵ鿡°Ô ´ëÀÀÇϰí ÀÖ½À´Ï´Ù.

Æú¸®´ºÅ¬·¹¿ÀƼµå ÁÖ»çÁ¦´Â ƯÈ÷ ÇǺΰú, Àç»ýÀÇ·á µî ¹Ì¿ë ÀÌ¿ÜÀÇ ºÐ¾ß¿¡µµ Àû¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÓ»ó ¿¬±¸ °á°ú, À§Ã༺ ¿©µå¸§ ÈäÅÍ, ±â¹Ì, ÁÖ±Ù±ú, ±â¹Ì, ½ÉÁö¾î ¹æ»ç¼± È­»ó Ä¡·á¿¡µµ È¿°ú°¡ ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ¶ÇÇÑ, »óóġÀ¯, ÈûÁÙ º¹±¸, ¿¬ºÎÁ¶Á÷ Àç»ý¿¡µµ Àû¿ëÀÌ °ËÅäµÇ°í ÀÖÀ¸¸ç, Á¤Çü¿Ü°ú ¹× Ä¡·áÀÇÇÐÀ¸·ÎÀÇ Å©·Î½º¿À¹ö °¡´É¼ºÀ» º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù.

Æú¸®´ºÅ¬·¹¿ÀƼµå ÁÖ»çÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ÃËÁø¿äÀÎÀº ¹«¾ùÀΰ¡?

Æú¸®´ºÅ¬·¹¿ÀƼµå ÁÖ»çÁ¦ ½ÃÀåÀÇ ±Þ°ÝÇÑ ¼ºÀå¿¡´Â ¿©·¯ °¡Áö ¿äÀÎÀÌ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç, ±â¼ú ¹ßÀü, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ȯÀÚ ÀνÄÀÇ Áõ°¡°¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

´õ ¸¹Àº ÇǺΰú ÀÇ»ç, ¼ºÇü¿Ü°ú ÀÇ»ç, ¼ºÇü¿Ü°ú Àǻ簡 Æú¸®´ºÅ¬·¹¿ÀƼµå ÁÖ»çÁ¦ ±³À°À» ¹Þ°í ÀÖÀ¸¸ç, ä¿ë·üÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÇÇÐ ÄÁÆÛ·±½º, ¿öÅ©¼¥ ¹× ½Ç½À ÇÁ·Î±×·¥Àº ÀÓ»óÀǰ¡ PN ÁÖ»çÁ¦ÀÇ °úÇаú ÃÖÀûÀÇ Àû¿ë ±â¼úÀ» ÀÌÇØÇÏ´Â µ¥ µµ¿òÀ» ÁÖ¸ç, ½ÃÀå ħÅõ¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

Æú¸®´ºÅ¬·¹¿ÀƼµå ÁÖ»çÁ¦´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç µî »õ·Î¿î ½ÃÀå ÁøÀÔÀ» ÃËÁøÇϱâ À§ÇØ ¿©·¯ Áö¿ª¿¡¼­ ¾à»ç ½ÂÀÎÀ» ȹµæÇß½À´Ï´Ù. Çѱ¹, ÀϺ» µî È­Àåǰ ±ÔÁ¦°¡ ¾ö°ÝÇÑ ±¹°¡µéÀÌ Ã¤ÅÃÀ» ÁÖµµÇϰí ÀÖÀ¸¸ç, Àü ¼¼°è ºäƼ Æ®·»µå¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.

¼ÒºñÀÚµéÀº ÀÚ½ÅÀÇ ÇǺΠ»ý¹°Çп¡ ¸Â´Â ¸ÂÃãÇü ºäƼ Æ®¸®Æ®¸ÕÆ®¸¦ ¿øÇϰí ÀÖ½À´Ï´Ù. PN ÁÖ»çÁ¦´Â ÀûÀÀ °¡´ÉÇÑ Ä¡·á ÇÁ·ÎÅäÄÝÀ» Á¦°øÇÏ°í ½Ã¼úÀÚ°¡ ȯÀÚÀÇ Çʿ信 µû¶ó ÁÖ»ç ±íÀÌ, ¾ç, ºóµµ¸¦ ¸ÂÃãÈ­ÇÒ ¼ö ÀÖµµ·ÏÇÔÀ¸·Î½á ÀÌ·¯ÇÑ ¿òÁ÷ÀÓ¿¡ Àß ÀûÀÀÇϰí ÀÖ½À´Ï´Ù.

º¼·ýÀ» ´Ã¸®Áö ¾ÊÀ¸¸é¼­µµ ¹Ì¹¦ÇÑ È¸ÃáÀ» Á¦°øÇÏ´Â »ýü ÀÚ±Ø Ä¡·á¿¡ ÁÖ¸ñÇÏ´Â ³²¼º ȯÀÚµéÀÌ ´Ã°í ÀÖ½À´Ï´Ù. Æú¸®´ºÅ¬·¹¿ÀƼµå ÁÖ»çÁ¦´Â ÀÚ¿¬½º·¯¿î ÇǺΠÀç»ýÀ» °¡Á®¿À°í, ¾ó±¼ÀÇ À±°ûÀ» ¹Ù²ÙÁö ¾ÊÀ¸¸é¼­µµ ´«¿¡ ¶çÁö ¾Ê´Â ¾ÈƼ¿¡ÀÌ¡ ¼Ö·ç¼ÇÀ» ¿øÇÏ´Â ³²¼ºµéÀÌ ¼±È£ÇÏ´Â ¼±ÅÃÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¼Ò¼È ¹Ìµð¾î¿Í ºäƼ ÀÎÇ÷ç¾ð¼­ÀÇ µîÀåÀº Æú¸®´ºÅ¬·¹¿ÀƼµå ÁÖ»çÁ¦¿¡ ´ëÇÑ ÀϹÝÀεéÀÇ °ü½ÉÀ» Å©°Ô ³ôÀ̰í ÀÖ½À´Ï´Ù. ÀνºÅ¸±×·¥, ƽÅå, À¯Æ©ºê µîÀÇ Ç÷§Æû¿¡¼­ Ä¡·á ÀüÈÄÀÇ °á°ú, ½Ç½Ã°£ Ä¡·á ¿µ»ó, ȯÀÚµéÀÇ ¸ñ¼Ò¸®¸¦ ÅëÇØ ÀþÀº Ãþ¿¡°Ô ´õ¿í Ä£±ÙÇÏ°Ô ´Ù°¡°¥ ¼ö ÀÖ´Â Ä¡·á¹ýÀÌ µÇ°í ÀÖ½À´Ï´Ù.

ºÎ¹®

¿ëµµ(´«, ÀÔ¼ú, À̸¶, Åμ± ¹× ±¤´ë»À, ±âŸ), ÃÖÁ¾ ¿ëµµ(¸Þµå½ºÆÄ, ¿¡½ºÅׯ½ ¹× ¼ºÇü ¼¾ÅÍ, º´¿ø)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Polynucleotides Injectables Market to Reach US$264.7 Million by 2030

The global market for Polynucleotides Injectables estimated at US$123.8 Million in the year 2024, is expected to reach US$264.7 Million by 2030, growing at a CAGR of 13.5% over the analysis period 2024-2030. Eyes, one of the segments analyzed in the report, is expected to record a 12.4% CAGR and reach US$118.3 Million by the end of the analysis period. Growth in the Lips segment is estimated at 14.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$33.7 Million While China is Forecast to Grow at 17.9% CAGR

The Polynucleotides Injectables market in the U.S. is estimated at US$33.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$55.7 Million by the year 2030 trailing a CAGR of 17.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.0% and 12.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.7% CAGR.

Global Polynucleotides Injectable Market - Key Trends & Drivers Summarized

What Are Polynucleotide Injectables and Why Are They Transforming Aesthetic and Regenerative Medicine?

Polynucleotide injectables are an emerging class of biostimulatory injectables used in aesthetic medicine and regenerative treatments to improve skin quality, hydration, and tissue repair. Polynucleotides (PNs) are long chains of nucleotides derived from natural DNA or RNA sources, typically extracted from salmon or trout DNA, due to their high biocompatibility and effectiveness in stimulating collagen production, wound healing, and cellular regeneration. Unlike traditional dermal fillers that primarily add volume, polynucleotide injectables work by stimulating fibroblast activity, increasing hydration, and enhancing skin elasticity, leading to long-term skin rejuvenation.

PN injectables are gaining popularity for their natural and regenerative approach to aesthetics. They help repair damaged skin, reduce fine lines, enhance skin texture, and improve elasticity without altering facial structure. This makes them ideal for patients who want subtle, natural-looking improvements rather than volumizing effects. Their anti-inflammatory and antioxidant properties also make them beneficial for rosacea, acne scars, and post-laser skin recovery, further expanding their applications in dermatology.

How Are Technological Advancements Enhancing Polynucleotide Injectables?

Technological innovations in biotechnology and bioengineering are advancing polynucleotide injectable formulations, making them more effective, longer-lasting, and safer for clinical use. One of the key advancements is the development of highly purified, stabilized polynucleotide chains with enhanced biocompatibility and reduced immunogenicity. These advanced formulations ensure that PN injectables are well-tolerated by the skin, minimizing the risk of adverse reactions or inflammation.

Another significant innovation is the integration of cross-linked polynucleotides that prolong bioactivity in the skin. Unlike unmodified PNs, which degrade more quickly, these new formulations allow for sustained skin rejuvenation and hydration over extended periods, reducing the need for frequent treatments. Some injectable brands now combine polynucleotides with hyaluronic acid, peptides, or antioxidants to enhance hydration, boost collagen synthesis, and provide multi-layer skin repair.

Moreover, the emergence of PN-based mesotherapy techniques is revolutionizing the way skin rejuvenation treatments are performed. Microinjections of polynucleotides into the superficial dermis create controlled microtraumas, triggering natural tissue regeneration. When combined with microneedling or laser treatments, PN injectables accelerate skin recovery and enhance treatment outcomes, making them an integral part of holistic skin rejuvenation protocols.

Additionally, AI-driven skin analysis and personalized medicine are helping practitioners tailor polynucleotide treatments based on individual skin conditions. With the aid of 3D imaging and AI-powered diagnostic tools, doctors can precisely determine the best PN formulations and injection protocols for each patient, maximizing efficacy and patient satisfaction.

What Are the Key Market Trends Driving the Demand for Polynucleotide Injectables?

The global demand for polynucleotide injectables is being driven by several key trends, reflecting a shift toward regenerative aesthetics, skin health optimization, and minimally invasive treatments.

Patients and practitioners are increasingly favoring biostimulatory treatments that work with the body's natural processes rather than artificially augmenting volume. Polynucleotide injectables fit this trend by promoting collagen remodeling and cellular regeneration, offering natural-looking, long-term results rather than the immediate but temporary effects of traditional fillers.

Younger patients are seeking preventive skincare treatments that support skin health and longevity, rather than waiting for visible signs of aging to appear. PN injectables are now being marketed as part of a "skin longevity" strategy, targeting early collagen depletion, dehydration, and oxidative stress before wrinkles become pronounced.

Initially popularized in facial rejuvenation, polynucleotide injectables are now being used for neck tightening, decolletage rejuvenation, hand revitalization, and even scalp treatments for hair restoration. Their regenerative properties are also making them valuable in scar revision, stretch mark treatment, and post-surgical healing, further broadening their market potential.

PN injectables are increasingly being integrated into combination treatments with radiofrequency (RF), laser therapy, microneedling, platelet-rich plasma (PRP), and dermal fillers. These multi-modal approaches amplify skin regeneration, enhance results, and extend the longevity of treatments. Clinics are adopting protocols that combine PN injectables with other biostimulatory treatments, catering to patients who want holistic skin restoration rather than isolated procedures.

Polynucleotide injectables are finding applications beyond aesthetics, particularly in dermatology and regenerative medicine. Clinical studies have shown their effectiveness in treating atrophic acne scars, rosacea, melasma, and even radiation burns. Additionally, they are being explored for wound healing, tendon repair, and soft tissue regeneration, indicating their potential crossover into orthopedic and therapeutic medicine.

What Are the Key Growth Drivers Behind the Polynucleotide Injectable Market?

Several factors are fueling the rapid growth of the polynucleotide injectable market, with technological advancements, regulatory approvals, and increasing patient awareness playing significant roles.

As more dermatologists, plastic surgeons, and aesthetic practitioners become trained in polynucleotide injectables, the adoption rate is rising. Medical conferences, workshops, and hands-on training programs are helping clinicians understand the science behind PN injectables and their optimal application techniques, driving wider market penetration.

Polynucleotide injectables are gaining regulatory approvals in multiple regions, facilitating their entry into new markets, including North America, Europe, and Asia-Pacific. Countries with strict cosmetic regulations, such as South Korea and Japan, are leading the adoption, influencing global beauty trends.

Consumers are demanding customized aesthetic treatments tailored to their unique skin biology. PN injectables fit well within this movement by offering adaptable treatment protocols, allowing practitioners to customize injection depth, dosage, and frequency based on the patient’s needs.

An increasing number of male patients are turning to biostimulatory treatments that offer subtle rejuvenation without adding volume. Polynucleotide injectables provide natural skin revitalization, making them a preferred choice for men seeking discreet anti-aging solutions without altering facial contours.

The rise of social media and beauty influencers has significantly boosted public interest in polynucleotide injectables. Before-and-after results, real-time treatment videos, and patient testimonials on platforms like Instagram, TikTok, and YouTube have made these treatments more accessible and appealing to younger audiences.

SCOPE OF STUDY:

The report analyzes the Polynucleotides Injectables market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Application (Eyes, Lips, Forehead, Jawline & Cheekbones, Others); End-Use (MedSpas, Aesthetic & Cosmetic Centers, Hospitals)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â